Austin, Texas – March 31, 2020 – Ethan Russo, MD, Founder/CEO and Nishi Whiteley, Co-founder/COO are pleased to announce the launch of CReDO Science, LLC (http://credo-science.com) a company devoted to research and development of disruptive technologies affecting the endocannabinoid system (ECS), the major homeostatic regulatory system of human and animal physiology.
Dr. Russo has almost 25 years’ experience in the ECS and cannabis research space including his high-profile work as Senior Medical Advisor at GW Pharmaceuticals and the Medical Monitor and Study Coordinator for the Sativex® and Epidiolex® trials, the only two cannabis-derived pharmaceuticals. A thought leader in the space, he is forever being asked, “What should we be working on?” CReDO Science will focus on exactly this. Initial CReDO Science efforts will concentrate in six areas for which provisional patents are in progress: a novel extraction technique for cannabis, an over- the-counter product for a common condition for which current treatments are toxic or poorly effective, a non-cannabinoid nutritional product from cannabis with expected broad anti-inflammatory effects, an inexpensive diagnostic test for two conditions that currently lack specific tools (so-called “diagnoses of exclusion”) and a novel Corona virus-killing disinfectant.
“We are very excited to be in a position to investigate and market new products, technologies and diagnostics leveraging the endocannabinoid system that portend to contribute towards meaningful advances in medicine, health and fitness, as well as industrial applications”, says founder and CEO Dr. Russo. “CReDO Science develops products and diagnostics that should be available internationally without the jurisdictional restrictions related to controlled substances, such as THC.”
The cannabis business worldwide is experiencing explosive growth as laws change and cannabis use becomes normalized. According to Arcview’s, State of Legal Cannabis Markets Report 7th Edition, the US total cannabinoid market alone is projected to be over $44.8B by 2024. CReDO Science co-founder Nishi Whiteley says, “These figures are staggering, especially when you consider that biopharma, nutraceutical and supplement companies have barely gotten into the game. These three areas are the new frontier in the cannabis space. With revered medical cannabis expert Dr. Ethan Russo at the helm, we aspire to solve the most important issues of the human endocannabinoid system with safe, non-toxic cannabis-based solutions.”
Beyond the proprietary internal R&D program, CReDO Science will be leveraging its principals’ knowledge and experience through consultation to and collaboration with meritorious partners and programs. These include Breeder’s Best (https://breedersbest.com/), a company seeking to develop improved cannabis genetics through conventional breeding, organic and regenerative culture, and best practices, (both Russo and Whiteley maintain leadership roles at Breeder’s Best due to the symbiotic nature of the two businesses), True Terpenes (https://trueterpenes.com/), the leading innovator and producer of GMP/ISO/FSSC-certified, effects-based terpenes and terpenoids from hemp and other plants, and a Canadian company developing pharmaceuticals derived from cannabis delivered via an innovative technique to treat serious illnesses currently lacking viable alternatives.
“We will distinguish ourselves from the many other companies in the cannabis space that are largely engaged in attempts to sell similar wares with questionable degrees of quality control in what I would term a ‘race to the bottom,” says Dr. Russo. “CReDO Science intends to raise the bar to bring safer and better cannabis products into mainstream commerce for improved endocannabinoid balance.”
To learn more about CReDO Science, visit www.Credo-Science.com.